View Mobile Site

Ask the Expert

Signal Photos


Biotech firm to acquire company

Boston Scientific expected to close deal by month’s end

Posted: November 9, 2012 2:00 a.m.
Updated: November 9, 2012 2:00 a.m.

Boston Scientific signed an agreement to acquire Vessix Vascular Inc., a privately held company based in Laguna Hills, Boston Scientific announced Thursday. The acquisition is expected to close by the end of this month.

Vessix developed a catheter-based system that interrupts the nerve connection to organs or parts of the body for the treatment of uncontrolled, medication-resistant hypertension — or high blood pressure — the leading attributable cause of death worldwide.

The Vessix system has proven in clinical studies to significantly reduce systolic blood pressure, using radiofrequency energy to disrupt the kidney’s sympathetic nerves, which result in hyperactivity leading to uncontrolled high blood pressure.

“Hypertension is a major global health care challenge, affecting more than 1 billion people worldwide,” said Mike Mahoney, president and chief executive officer at Boston Scientific.

The new treatment represents a potential breakthrough therapy for the treatment of uncontrolled hypertension and is an important part of the Boston Scientific growth strategy, he said.

“The acquisition of Vessix Vascular adds a second generation, highly differentiated technology to our hypertension strategy while accelerating our entry into what we expect to be a multi-billion dollar market by 2020,” Mahoney said.


Commenting not available.
Commenting is not available.


Powered By
Morris Technology
Please wait ...